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Although insulin effectively blocked hormone-stimulated glycerol output in adipocytes or phosphorylase
activation in hepatocytes, the inhibitory effect of insulin on cAMPanalog-stimulated cells depended onthe
CAMP analog used. Of the 20 analogs tested in adipocytes and 13 tested in hepatocytes, the effects of about
half of them were effectively blockedby insulin,
whereas the effects of many of them were not inhibited
at all. In order to approach the explanation for this
discriminative insulin action, the inhibitory effects of
insulin on the responses to the analogs in the intact
cells were correlated with the in vitro cAMP analog
specificity for thehepatocyte CAMP-dependent protein
kinase isozymes and the low K,, hormone-sensitive
phosphodiesterasesfrom both cell types.N o correlation
was found between insulin resistance of analog-stimulated hepatocyte phosphorylaseand the
concentration
of analog required in vitrofor half-maximal activation
of either type I or type I1 CAMP-dependent protein
kinase from hepatocytes. However,a good correlation
was found betweeninsulin resistance of cAMP analogstimulated responses and the analog IsOvalues for the
phosphodiesterase from both cell types. Using a new
method capable of measuring hydrolysis at low analog
concentrations, several of those analogs which had
relatively 1ow;but not high, phosphodiesteraseIsOvalues were shown to be directly hydrolyzed by the low
K , adipocyte phosphodiesterase. The insulin inhibition
of cell responses whenstimulated by hydrolyzable analogs, but not by poorly hydrolyzable analogs, is best
explained by insulin stimulation of the low K , phosphodiesterases from both cell types.

Lipolysis in adipocytes and glycogenolysis in hepatocytes
are increased by catabolic hormones which elevate cAMP and
activate CAMP-dependent protein kinase. In the presence of
the anabolic hormone insulin, these effects are partially or
completely blocked,but the mechanism is not certain. It has
been demonstrated in a number of laboratories that insulin
decreases intracellular levels of cAMP in fat (1,2) andliver
in
(3-7) tissues, particularly when they are elevated. Some evidence suggests that this is due to an inhibition of adenylate
cyclase (8,9), but this is notuniversally accepted (7, 10-12).
Alternatively, it has been proposed that insulin stimulates a
low K,,, cAMP phosphodiesterase to account for the decrease
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in cAMP (13-17), although the physiological significance of
this effect is questioned (18). Some investigators have been
unable to detect a lowering of cAMP under certain conditions
of insulin action (19-24). Other possible mechanisms include
increases in phosphoprotein phosphatase(s) (25) and protein
kinase inhibition (26, 27) by this hormone. The latter effect
would result, in part, from an inhibition of protein kinase
activity secondary to a decrease in cAMP due to phosphodiesterase activation. However, it has been suggested that insulin reduces the sensitivity of protein kinase to cAMP and
thereby inhibits theenzyme without lowering CAMP (28).
To
account for hepatic insulin action, a recent study concluded
that inhibition of CAMP-dependent protein kinase occurs
independently of cAMP changes and phosphodiesterase activation (23). Several groups (25,29-31) havepartially purified
low molecular weightpeptide(s) which couldmediate some or
all of the effects of insulin. In order to account for the many
and diverse actions of insulin, it is not unreasonable to consider that after insulin binds to the receptor, there aremultiple
pathways of action.
A study was recently conductedusingcyclicnucleotide
analogs to stimulate lipolysis in isolated rat adipocytes (32).
The pattern of analog effects indicated that they were acting
through CAMP-dependent protein kinase activation. This
provided the groundwork for the present study which demonstrates that, although insulin blocks hormonal effects, it
does not block the effects of all cAMP analogs usedto stimulate adipocyte glycerol
output and hepatocytephosphorylase.
In order to examine the reason for the discriminative insulin
action, both cell types were thoroughly characterized for
cAMP analog potency and specificity in the presence and
absence of insulin, .and the specificities of the same cAMP
analogs were determined for the isolated low K, phosphodiesterases and CAMP-dependentprotein kinases. These experiments present a unique approach to the use of cAMP
analogs to study the mechanism of insulin action on cyclic
nucleotide-mediatedprocesses. A preliminary report of these
findings has previously appeared (33).
EXPERIMENTALPROCEDURES

Adipoqte Experiments-Adipocytes were isolated by collagenase
treatment of rat epididymal fat pads according to the method of
Rodbell (34). Allaspects of adipocyte experiments were as previously
described (32), with some exceptions. Incubations were for 30 min at
37 “C.Cells were preincubated for 8-12 min in thepresence or absence
of 1 nM insulin before the addition of hormone or cyclic nucleotide
analog. There was no effect of insulin on basal lipolytic rates. A
maximal lipolytic response (10-12 pmol of glycerol/g of fat, dry
weight/30 min) was determined using 10 p~ epinephrine in the
presence of200 p~ isobutylmethylxanthine. Glycerol release was
determined after 30 min of incubation as a measure of lipolysis
according to the method of Wieland (35), as previously described
(32).
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Hepatocyte Experiments-Hepatocytes were prepared by collagen- LaRoche. Glucagon and insulin were generous gifts from Lilly. Other
ase perfusion of rat livers, as described by Blackmore and Exton (36). materials were as described in Ref. 32.
Briefly, hepatocytes were isolated from the livers of 180-220-g rats.
The livers were perfused insitu at 37 "C with Ca2+-free KrebsRESULTS
Henseleit bicarbonate buffer, pH 7.4, containing 11 mM glucose, 5
The Effect of CAMPAnalogs on Physiological Responsesin
mM sodium pyruvate, 5 mM sodium L-glutamate, and washed human
erythrocytes (10% hematocrit). After an initial noncirculating flow Adipocytes and Hepatocytes-From the results of recently
through the liver with the above buffer (50 ml), a0.4 mg/ml collagen- conducted studies using cAMP analogs to stimulate lipolysis
ase solution (Worthington, type I) was recirculated through the liver in isolated rat adipocytes (32) and glycogenolysis in hepatofor 30 min. The cells were shaken away from the digested liver, poured
through nylon mesh, and centrifuged a t 50 X g for 2 min. Cells were cytes (39), it was concluded that analogs act by crossing the
resuspended in the above buffer containing 1.5% gelatin and prein- cell membrane to directly activate the CAMP-dependent procubated for 10 min in the presence or absence of 6 nM insulin before tein kinase. In the present study, a large number of cAMP
the addition of a series of concentrations of glucagon or cyclic nu- analogs were tested in both hepatocytes and adipocytes.
cleotide analog. After a 5-min incubation, a 500-pl aliquot of the cell
The most interesting feature concerning analog efficacy
suspension was removed, frozen in liquid nitrogen, and stored a t
was
the striking difference in sensitivity between adipocytes
-70 "C until assayed. Pellets were partially thawed, homogenized,
and assayed for phosphorylase by measuring the incorporation of and hepatocytes (Table I). Adipocyte lipolysis was sensitive
['4C]Glu-1-P into glycogen in the absence of 5'-AMP, as previously to cAMP analogs inthe millimolar concentration range,
described (36). In theabsence of glucagon,there was little or no effect whereas hepatocyte phosphorylase was activated in the miof insulin on the basal activity of phosphorylase. A maximal phos- cromolar concentration range. For example, the ECbO
(concenphorylase activity (a 3-4-fold activation) was elicited by 10 KIM
tration
required
for
half-maximal
activation)
for
8-thioethylglucagon (28-32 pmol of Glu-1-P/g, wet weight/min).
Preparation and Assay of Adipocyte and Hepatocyte Particulate cAMP in adipocytes was about 1mM, whereas the same extent
Phosphodiesterase-The low K,,, phosphodiesterase from adipocytes of phosphorylase activation in hepatocytes required only 0.3
and hepatocytes were prepared and assayed according to themodified PM. Similarly, half-maximal activation of adipocyte lipolysis
method (31) of Loten et al. (16). These enzymes have been shown to required approximately a 3,000-fold higher concentration of
be sensitive to insulin stimulation when the phosphodiesterases are 8-bromo-CAMP and a 10,000-fold higher concentration of 8partially purified from hormone-treated intact cells (13, 14, 16).
Consistent with other reports (13, 14), the concentration of cAMP in thioparachlorophenyl-CAMP than was required for the same
this study required for half-maximal activity of the enzymes from extent of hepatocyte phosphorylase activation. Generally,
both cell types was between 0.4-0.8 p ~ Im. values were determined, hepatocytes were 100-10,000 times more sensitive than adias previously described (32), using a concentration of0.1 p~ [3H] pocytes to cAMP analog stimulation when comparing these
cAMP as substrate in the standard phosphodiesterase assay. Cyclic two physiological processes.
nucleotide analogs were added to thereaction mixture in a wide range
Another aspect of analog potency concerned a comparison
of concentrations. The
value was taken as a measure of analog
of
relative potencies within each cell type. The analogs folcompetition for [3H]cAMP hydrolysis and was expressed asthe
concentration of analog which inhibit [3H]cAMPhydrolysis by 50%. lowed a similar, but not identical, rank order of potency in
Determination of Cyclic Nucleotide Analog Hydrolysis-CAMP an- adipocytes and hepatocytes. For analogs modified at the 8alogs were incubated with adipocyte phosphodiesterase at concentra- carbon of the adenine ring, 8-thio derivatives were among the
tions equivalent to their 150value. After various times of incubation
(0-45 min), aliquots of the reaction mixture were boiled for 5 min most potent agents and were considerably more potent than
and appropriately diluted. The concentration of cAMP analog, a t 8-amino derivatives in both cell types (Table I). For example,
zero time and at various times following incubation with the phos- the EC50 for 8-thiomethyl-CAMP was 8- and 12-fold lower
phodiesterase, was determined using a standard curve for each analog than that of 8-aminomethyl-CAMP in hepatocytes and adiin a protein kinase assay. The adipocyte or bovine heart type I1 pocytes, respectively. In both cell types, 8-thioethyl- and N6protein kinase was used as enzyme and synthetic heptapeptide as benzoyl-CAMP werepotent agents, N'-butyryl- and 8-bromosubstrate, as previously described (32, 37). Duplication incubations
of cAMP analog and phosphodiesterase were carried out on a t least cAMP were of intermediate potency while 8-amino derivatives
three different phosphodiesterase preparations, and thecAMP analog were least potent. However, some analogs varied in relative
concentration was determined from a t least two different dilutions of potency between the cell types. 8-Thioparachlorophenyl- and
boiled incubation mixture.
8-thioparanitrobenzyl-CAMP were the most potent in hepaApparent K, Determination for Cyclic Nucleotides-The type I and tocytes and of intermediate potency in adipocytes. Conversely,
type I1 protein kinases from hepatocytes were completely separated
8-thioisopropyl-CAMP and N6-carbamoylpropyl-CAMPwere
by DEAE-cellulose column chromatography, as previously described
(38). The adipocyte type I1 protein kinase was purified in a similar
TABLE
I
manner, as described in Ref. 37. The apparent K, values for cAMP
and cAMP analogs were determined in a standard protein kinase
Potency of CAMPanalogs in isolated cells
assay, using synthetic heptapeptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly)
ECso
ECso
as substrate, as described in Ref. 32. The apparent K, is defined as
nucleotide
Cyclic
adipocyte
analog
hepatocyte
the concentration of cAMP analog required for half-maximal activalipolysis
phosphorylase
tion of the enzyme. Experiments for the hepatocyte enzymes were
PM
PM
carried out with a total protein kinase activity of 1200-1800 pmol of
500
3.0
N6-Carbamoylpropyl-CAMP
32P incorporated per min/ml of enzyme and a basal activity ratio
500
2.0
8-Thioisopropyl-CAMP
(activity in the absence divided by activity in the presence of 5 p~
0.5
700
N'-Benzoyl-cGMP
CAMP)of 0.10-0.15 for type I and 0.02-0.08 for type 11. Apparent K,
0.3
900
8-Thioethyl-CAMP
values for the adipocyte protein kinases were determined as described
1,000
0.1
8-Thioparachlorophenyl-CAMP
in Ref. 37. The apparentK. value is expressed as K: which is defined
1,000
0.5
8-Thiomethyl-CAMP
as theratio of the apparentK,, for cAMP divided by the apparent K ,
0.1
1,200
8-Thioparanitrobenzyl-CAMP
for the cAMP analog.
1,900
4.8
fl-Butyryl-CAMP
Material~-[~~C]Glu-l-P
was obtained from ICN. 8-Thioparachlo1.3
3,900
8-Bromo-CAMP
rophenyl-CAMP was purchased from Boehringer Mannheim. N68-Amino-CAMP
6,100
Diethyl-, N6-carbamoylpropyl-, 6-thiomethyl-,b-thioparanitroben7,900
8-Aminomethyl-CAMP 6.0
zyl-, and 2-trifluoromethyl-CAMPwere generously provided by Drs.
8,600
60.0
8-Aminohexylamine-CAMP
Jon Miller and Robert Suva of Biochemical Research Laboratory,
>15,000
8-Aminobenzyl-CAMP
Life Sciences Division, SRI International, Menlo Park, CA.RO-7>15,000
30.0
cIMP
2956was akind gift from Dr. Peter F. Sorter from Hoffmann-
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N6-carbamoylpropyl-CAMPdiffered slightly for the phosphodiesterases from the two cell types.
The Effect of Insulin on Hormone- and CAMP Analogstimulated Responses in Adipocytes and Hepatocytes-Before
the effects of insulin on analog-stimulated cell responses were
investigated, control experiments were carried out with several concentrations of epinephrine in adipocytes or glucagon
in hepatocytes in the presence and absence of a series of
insulin concentrations (data not shown). Insulin (0.1-10 nM)
inhibited epinephrine-stimulated lipolysis 90-100% when the
lipolytic effect was less than 50% of a maximal response.
When lipolysis was stimulated 70-80%of the maximum (1
p~ epinephrine), insulin(0.1-1 nM) inhibited glycerol release
by only 70-80%. At this higher level of stimulation, insulin
at 10 nM was less effective as a lipolytic antagonist (50-60%
inhibition). This biphasic insulin inhibition of epinephrinestimulated lipolysis is in agreement with previously published
data (2). Since a maximal insulin inhibition at all levels of
epinephrine stimulation was observed by 1 nM insulin, this
concentration was chosen as a potential antagonist
to analogstimulated lipolysis.
Similar experiments were carried out in the presence or
absence of insulin with glucagon-stimulated hepatocytes.
When phosphorylase activity was stimulated to about 70% of
the maximum (0.1-1.0 nM glucagon), insulin (0.01-10nM)
caused a concentration-dependent decrease in phosphorylase
activity. A maximal inhibition of70-80%was
seen with
approximately 6 nM insulin. This concentration of insulin
was used in experiments where the effects of insulin on
analog-stimulated hepatocytes were investigated.
It was previously shown that insulin blocksexogenous
CAMP-stimulated lipolysis or glucose production in adipocytes (2) and hepatocytes (23), respectively. In this study,
insulin was tested as a potential antagonist
using a large
number of cAMP analogs as agonists. Hormone and cAMP
analog concentration curves were generated in the presence
and absence of insulin for hepatocyte glycogenolysis (Fig. 2)
and adipocyte lipolysis (Fig. 3). Five representative analog
concentration curves for each cell type are shown. In both
cell types, responses stimulated bysome analogs, but not
others, were sensitive to insulin inhibition. Responses to
analogs such as 8-thioethyl-, %amino-, and 8-bromo-CAMP
in adipocytes and 8-thioethyl-, 8-thioisopropyl-cAMP, and
cIMP in hepatocytes were sensitive to inhibition by insulin.
In both cell types, responses to N6-benzoyl- and N6-monobutyryl-CAMP were resistant to insulin inhibition. The data
in Table I1 for insulin inhibition was compiled from concentration curves like those in Figs. 2 and 3 using 20 cAMP
analogs in adipocytes and 13 analogs in hepatocytes. The per
cent insulin inhibitionwas determined from the region of the
analog concentration curves where insulin causes the greatest
inhibition. In adipocytes, insulin was most effective at inhibiting lipolysis when the analog-stimulated glycerol release was
30-60% of the maximal response. In hepatocytes, insulin was
most effective when phosphorylase was stimulated 20-40% of
the maximum. It can be seen that, in general, analog-stimulated responses, which were sensitive or resistant to insulin
inhibition in adipocytes, were the same in hepatocytes. There
I
I
I
I
were two primary exceptions to this generalization. The re0
10
20
30
40
50
sponse to 8-thioisopropyl-CAMP was blocked by insulin in
Phosphodiesterase Incubation Time (minutes)
adipocytes, but not in hepatocytes. The effect of N6-carbaFIG. 1. Time course for the direct hydrolysis of
cAMP ana- moylpropyl-CAMP wasnot inhibitedby insulin in adipocytes,
logs by the lowK , phosphodiesterase from rat adipose
tissue.
Analog hydrolysis was determined as described under “Experimental but was inhibited in hepatocytes.
It should be pointed outthat theeffect of insulin on analogProcedures.” Eachpoint represents the mean of duplicate incubations
in a typical experiment. a-S-pClph-cA, 8-thioparachlorophenyl- stimulated responses should not be due to differential analog
CAMP;a-Br-cA, 8-bromo-CAMP.
penetration of the cell membranes since all insulin effects are

most potent in adipocytes, but of intermediate potency in
hepatocytes.
Correlation of Analog 150 Values for Phosphodiesterase with
Actual Analog Hydrolysis-The phosphodiesterase I50value of
cAMP analogs was assumed to represent competitive inhibition of [3H]cAMP hydrolysis. However, it was possible that
some analogs were either acting as noncompetitive inhibitors
or binding to thehydrolytic site without being hydrolyzed. It
was therefore important to determine if the analogs were in
fact being hydrolyzed. Since few of the analogs commonly in
use are radioactively labeled, an alternative method was used
to determine direct analog hydrolysis. The concentration of
several analogs was measured before and after incubation
with the low K , phosphodiesterase isolated from rat fat pads.
Analog concentration was determined using a standardcurve
for protein kinase activation with each analog tested. As a
control, hydrolysis of unlabeled cAMP in this procedure was
compared with hydrolysis of [3H]cAMPin the standard
phosphodiesterase assay. The rates of hydrolysis using the two
procedures were in good agreement. Fig. 1 shows a typical
time course of hydrolysis using two cAMP analogs tested by
this technique. 8-Bromo-CAMPand 8-thioparachlorophenylcAMP were incubated with the adipose tissue phosphodiesterase at 17 and 22 p ~ respectively.
,
Thesearenear
the
respective analog 150concentrations (Table 11). Under these
conditions, about 40% of 8-bromo-CAMP and about 25% of
8-thioparachlorophenyl-CAMP were hydrolyzed in 30 min.
Several other cAMP analogs were also tested at concentrations at or near theirIs0values after a30-min incubation with
the phosphodiesterase (data not shown). 8-Amino-, 8-aminomethyl-, and 8-thiomethyl-CAMPwere also significantly hydrolyzed (20-40%) under these conditions. However, hydrolysis of N‘”benzoy1- and N6-monobutyryl-CAMPwas not readily detected.
Under the conditions used in these studies, the rates of
hydrolysis of these analogs could not be compared to one
another or to cAMP since they were tested at different concentrations.Theseexperiments
nevertheless demonstrated
that some analogs do serve as substrates for the phosphodiesterase, albeitat higher concentrations than are required for
cAMP hydrolysis. For allanalogs tested, hydrolyzable analogs
(Footnote b in Table 11) have relatively low 150values, and
nonhydrolyzable analogs (Footnote c in Table 11) have relatively high 150values. The analog 150values for the phosphodiesterases from both cell types were in good agreement
(Table I1 and Fig. 4). Only the 150values for N6-benzoyl-and
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TABLEI1
Comparison of insulin effects with CAMPanalog 150 values for phosphodiesterases
Hepatocyte
Cyclic nucleotides

cAMPb
8-Thioethyl-CAMP
8-Aminomethyl-CAMPb
N6-Diethyl-CAMP
8-Bromo-CAMPb
8-Thioparachlorophenyl-CAMPb
6-Thiomethyl-CAMP
8-Thiomethyl-CAMP
&Amino
8-Thioisopropyl-CAMP
8-Thiobenzyl-CAMP
8-Thioparanitrobenzyl-CAMP
N6-Aminohexylcarbamoylmethyl4AMP
N6,02'-Dibutyryl
N6-Carbamoylpropyl-CAMP
N6-Benzoyl-CAMP"
N'-Butyryl-cAMP
8-Hydroxy-cAMP
8-Aminohexylamino-CAMP
8-Aminobenzyl-CAMP
cIMP

Adipocyte
Insulin
inhibition
(lipolysis)

PDE"Iw

%

PM

70
100
100
90
90
80
80
75
70
60
35
15
15
0
0
0
0
0
0
0

0.7
79
33
84
14
27

46
40
280
48
25
>1,000
111
492
90
597
>1,000
202
0.9

Insulin
inhibition
(phosphorylase a)

PDE"Is0

%

PM

60
50
50

1
51
83

70
30

45
36

30

80

0

370

20

28

50
0
0

140
355
980

0

>1,000

60

Other agonists
Epinephrine
90
Glucagon
70
R0-7-2956
90
47
Isobutylmethylxanthine
90
3
PDE, phosphodiesterase.
Cyclic nucleotides hydrolyzed by the adipocyte phosphodiesterase when tested at their I,, concentration.
Cyclic nucleotides not hydrolyzed bythe adipocyte phosphodiesterasewhen tested at their I50 concentration.

compared a t equipotent concentrationsof analogs. Therefore,
one would not expect a correlation between the effects of
insulin onanalog-stimulated responses and thebutanol/water
partition coefficient of the analog (32), and none was apparent
(data not shown).
Thereare several points of interest to the differential
insulin inhibitionof analog-stimulated responses in these cell
types(Table I1 and Fig. 4). The responses generated by
analogs which have modifications at C-8 of the adenine ring
were generally inhibited by insulin if the derivative was not
bulky and/or hydrophobic. For instance, lipolytic responses
to 8-amino- and 8-aminomethyl-CAMP were inhibited 7090%, but responses to analogs with bulky substituents, such
as 8-aminohexylamino- and 8-aminobenzyl-CAMP, were not
inhibited significantly by insulin. Likewise, lipolytic responses
generated by 8-thioethyl- and 8-thiomethyl-CAMP were
blockedby insulin (75-90%). However, lipolytic responses
stimulated by 8-thioisopropyl-, 8-thiobenzyl-, and 8-thioparanitrobenzyl-CAMP were inhibited by insulin by 60, 35, and
15%,respectively. These same generalizations were true when
phosphorylase activation was analyzed. At least two exceptions to the above generalization were recognized. The lipolytic response of 8-thioparachlorophenyl-CAMP,containing a
relatively bulky group, was inhibited by insulin while 8hydroxy-CAMP, containing a relatively non-bulky group, was
not. Although fewer N6 analogs were studied in the intact
cells, responses to these analogs were generally not inhibited
by insulin. The exceptions to this are the adipocyte response
to N'dmethyl- and 6-thiomethyl-CAMP and thehepatocyte
response to N6-carbamoylpropyl-CAMP.
Further studies were designed to find an explanation for
the discriminative insulin inhibition of responses to cAMP

analogs. It was reasoned that if insulin action on lipolysis and
glycogenolysis was due to stimulation of phosphodiesterase
activity, insulin would only inhibit thoseresponses generated
by analogs whichwere hydrolyzed by phosphodiesterase.
Therefore, the effects of insulin on analog-stimulated responses were correlated with the analog 150value for the low
K, phosphodiesterases from adipocytes and hepatocytes (Fig.
4).The top and bottom panels of Fig. 4 represent hepatocyte
and adipocyte experiments, respectively. The height of each
bar represents the analog 150value for the phosphodiesterase
isolated from the each cell type..The analog Isois defined as
the concentration of analog required to cause a half-maximal
inhibition of cAMP hydrolysis by the respective phosphodiesterases using 0.1 ~ L M[3H]cAMP as substrate. Analogs were
arbitrarily divided into two general categories. Insulin-sensitive analog responses (Fig. 4, striped bars) were inhibited by
insulin by 260% in adipocytes and 230% in hepatocytes.
Insulin-resistant analog responses were inhibited little,if any,
by insulin. For example, insulin inhibited analog-stimulated
responses in hepatocytes and adipocytes to 8-bromo- and 8thioparachlorophenyl-CAMP, both of which had relative low
phosphodiesterase Imvalues (Fig. 4 and Table 11) and were
susceptible to phosphodiesterase hydrolysis (Fig. 1).Insulin
did not inhibitanalog-stimulated responses in either cell type
to N'-benzoyl- and N6-monobutyryl-CAMP, both of which
had relatively high 150values (Fig. 4 and Table 11), and were
not apparently hydrolyzable. 8-Thiobenzyl-, S-thioparanitrobenzyl-, and N6-carbamoylmethyl-CAMPwere not included
since these analog responses were only weakly inhibited by
insulin(Table 11). There was clearly astrong correlation
between the 150value for an analog and itsresponsiveness to
insulin inhibition in bothcell types. Although the correlation
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FIG.2. The effects of
insulin
on
hormoneand
CAMP
analog-stimu14
latedphosphorylaseactivationin
isolated
hepatocytes.
Hepatocytes
12
were prepared as described under “Ex- x
perimental Procedures.” Cells were f 10
preincubated in the absence (0)or pres- ence (0)of 6 nM insulin for 10 min.
e
Hormore or’cAMP analogs were added E
at various concentrations, and cells were 2
incubated for an additional 5 min. Aliquots of 500 pl were removed and im- E
mediately frozen in liquid nitrogen and 2
stored at -70 “C until assayed. Pellets f
were partially thawed, homogenized, and
24
phosphorylase activity was determined 5
in the absence of 5’-AMP by the incorporation of glucose 1-phosphate into gly22cogen as described under “Experimental
20Procedures” and as previously described
(36). Dose-response curves in the pres- p leence or absence of insulin were deter16mined for each cAMP analog on threeor I
more different hepatocyte preparations.
14
Typical experiments are represented.
INS, insulin; G-1-P, glucose 1-phos12phate.

2l
22

N
-I -

$

rf

1041

16”

169

GLUCAGON (M)

-

n”

5

=
0

-

N%mroyl-cAMP

(MI

I2

FIG.3. The effects of insulin on
hormone- and CAMP analog-stimulated lipolysis in isolatedadipocytes. Adipocytes were isolated and incubated in the absence (0)and presence
(0)of insulin (1nM) prior to the addition
of hormone or CAMPanalog and assayed
for glycerol release as a measure of lipolysis as described under “Experimental
Procedures.” Dose-response curves in
the presence and absence of insulin were
determined for each cAMP analog on
three or more different adipocyte preparations. Typical experiments are represented. INS, insulin.

5
5

-INS

E

;
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+INS

10
Id
Epinephrine ( M i

IO

Id
8-Amino-CAMP [ M )

Io3 x IO’
8-ThioethyI-cAMP(M)

3x I d

g Iz
5
IO
I10

a

2

I

p

N“-Benzoyl-CAMP

(M)

was unmistakable, it was not perfect. 8-Thioisopropyl-CAMP
had a similar 15,,value for the phosphodiesterase from both
cell types, but itsresponse wasinhibited by insulin in adipocytes and not in hepatocytes. In hepatocytes, N‘-carbamoylpropyl-CAMP had a relatively low Iso value and its response
was inhibited by insulin, while in adipocytes this analog had
a higher Iso valueand itsresponse was not inhibited by insulin.
Although in both cell types there was a strong correlation
between the effects of insulin on cAMP analog-stimulated
responses in both cell types and the phosphodiesterase

3 ~ 1 6 ~ Id3
N6.-8utyryl-cAMP

3.10
(M)

values, this did not completely rule out the possibility that
insulin acted on the protein kinase. This appeared to be a
possibility in adipocytes becausethere was a vague correlation
between the sensitivity of cAMP analog effects to insulin
antagonism and theapparent affinity of analogs on adipocyte
type I1 protein kinase (37). Further experiments were therefore carried out to correlate the hepatocyte responsivenessto
insulin and the cAMP analog specificity for hepatocyte
type
I and type I1 protein kinases. For this evaluation,the apparent
K , values for cAMP analogactivation of protein kinase iso-
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cAMP
Analog-stimulated
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Cells
protein kinases and the effect of insulin on hepatocyte phosphorylase. For example, insulin blocked the responses to
cIMP (low K2 for both isozymes), 8-bromo-CAMP(intermediate K2 for both isozymes), and 8-thioparachlorophenylCAMP (high K2 for both isozymes). Conversely, responses to
analogs which had either low or intermediate K: values were
not blocked by insulin.

Hepatocyte
Phosphorylase

0 No I n s u l i n I n h i b i t i o n

a2 30% I n s u l i n I n h i b i t i o n

DISCUSSION

-I
.3
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;

n

1000-

3

Adipocyte
Lipolysis

0 No I n s u l i n I n h i b i t i o n

FIG.4. Correlation of hepatocyte and adipocyte low K,,,
phosphodiesterase 160 values with the effect of insulin on
analog-stimulated cell responses. The effect of insulin on hepatocyte phosphorylase activation (top p a w l ) and adipocyte lipolysis
(bottom panel) was determined for each cAMP analog as illustrated
in Figs. 2 and 3. Cell responses to cAMP analogs which were not
inhibited by insulin are shown by open bars, and responses which
were inhibited by insulin (230% in hepatocytes and 260% in adipocytes) are shown by striped bars. The extentof insulin inhibition was
determined at agonist concentrations eliciting 30-50% of a maximal
response. The height of each bar indicates the 150 value for each
cAMP analog using the low K,,, phosphodiesterase from each cell type
as described under “ExperimentalProcedures.” g-S-pCZph, 8-thioparachlorophenyl-CAMP; 8-Br, 8-bromo-CAMP;8-S-CzH5, 8-thioethylCAMP; 8-SXH3, 8-thiomethyl-CAMP; 8-NH-CH3, 8-aminomethylCAMP; 8-NH2, 8-amino-CAMP; N‘CONH-P, N6-carbamoylpropylCAMP; N6(C2H&, N‘-diethylamino-CAMP; 8-S-isoP, 8-thioisopropyl-CAMP;N‘Bzl, N6-benzoyl-CAMP; 8-NH-Ben, 8-aminobenzylCAMP;N6-Bt, N6-monobutyryl-CAMP;8-AHA, 8-aminohexylaminoCAMP.

zymes (concentration of cyclic nucleotide required for halfmaximal activation) are expressed as a relative value or K2
[K, (cAMP)/K, (cyclic nucleotide)]. Consequently, values
compound
greater than or less than one indicate that the test
is superior or inferior, respectively, to CAMP. Hepatocytes
were chosen for these studies because they were much more
sensitive than adipocytes to cAMP analog stimulation, and
therefore more cAMP analogs which were poor activators of
protein kinases could be tested. This was particularly true of
cIMP which was a poor lipolytic agent, for reasons previously
described (32). This analog was an effective glycogenolytic
agent, albeit a t high concentrations (Fig. 2). Furthermore,
hepatocytes were chosen because they contain both type
I and
type I1 protein kinases. It is readily apparent inFig. 5 that no
correlation existed between the
of either type I or type I1

IC:

Cyclic nucleotide analogs act on intact cells by crossing the
cell membrane and activating the CAMP-dependent protein
kinases. The predominant, if not the only, effect of all tested
cAMP analogs is directly on the CAMP-dependent protein
kinase (32). This is supported by studies using cAMP analogs
which selectively bind to one or the other of two intrasubunit
cyclic nucleotide-binding sites on the regulatory subunit (40).
Since these sites interact with positive cooperativity (40),
addition of a combination of two analogs, one selective for
one site andthe second for the othersite, causes a synergistic
activation of the protein kinase (32, 40). In all respects, the
behavior of site-selective cAMP analog combinations on the
cooperativity of binding and activation of purified protein
kinase is equivalent to the behavior of the same analog
combinations on protein kinase-mediated metabolic responses in intact cells (32, 39).
Since the low K,,, phosphodiesterase from these two cells
have been shown to be stimulated by insulin, this enzyme is
a logical candidate for the observed discriminative insulin
action. For the vast majority of the analogs tested in bothcell
types, insulin blocks the responses to analogs with relatively
low Ibovalues for phosphodiesterase but does not block the
cell responses to analogs with relatively high 150values. The
simplest interpretation of these results is that insulin blocks
the cell responses only if the analogs are relatively hydrolyzable. To test the assumption that a low 150value is correlated
with analog hydrolyzability, a method has been developed
using the CAMP-dependent protein kinase to directly measure
disappearance of the analog following hydrolysis. The disadvantage of this method is that it measures substrate disappearance ratherthan
product formation. However, this
method has a t least two advantages over previous methods
which measured analog hydrolysis by phosphate release or
paper chromatography (41). First, very low levels of cAMP
analog can be used ( 2 5 nM) compared to much higher concentrations (-1 mM) required by the previous methods. Second, because of the sensitivity of protein kinase, very small
changes in analog concentration canbe detected. Five analogs
which have been tested for direct phosphodiesterase hydrolysis have relatively low 150 values and areshown to be hydrolyzed. The responses to these same analogs are inhibited by
insulin. Analogs such as N6-benzoyl- and N6-monobutyrylcAMP have higher 150 values and are not hydrolyzed. The
responses to these analogs are not inhibited
by insulin. Insulin
inhibition of responses to only those analogs with low 150
values (hydrolyzable analogs) suggests that the activation of
the phosphodiesterase is an important mechanism of insulin
action. The differences in insulin inhibition do not appear to
be due to analog effects on protein kinase since no correlation
is found between the K2 for the hepatocyte protein kinase
isozymes and the effects of insulin on hepatocyte phosphorylase.
Although low Iso values are well correlated with analog
hydrolysis for the analogs tested, this relationship will not
necessarily hold for all analogs with low 150 values. For instance, if an analog readily binds to thehydrolytic site of the
phosphodiesterase but is nothydrolyzed, a low 150 value could
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FIG. 5. Correlation of hepatocyte
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230% Insulin
Inhibition

3.6

values with the effect of insulin on
analog-stimulated phosphorylase
activation. The effect of insulin on hepatocyte phosphorylase activation was
determined as described in Fig. 2. The
height of each bar indicates the Kb value
for each cAMP analog using partially
purified hepatocyte type I and type I1
protein kinase as described under “Experimental Procedures.” The Kbis defined as the apparent KOof cAMP (type
I, 130 nM; type 11,90 nM) divided by the
apparent K, for cAMP analog. Abbreviations are indicated in Fig. 4.

be obtained. Analogs such as 8-thioparanitrobenzyl- and 8thiobenzyl-CAMP, whose responses in adipocytes are minimally inhibited by insulin, may fit this classification. 150 values
have been determined for N6-benozyl- and N‘-monobutyrylCAMP,yet hydrolysis is not detected when tested at or near
their 150 values. This suggests that they inhibit [3H]cAMP
hydrolysis by a noncompetitive mechanism, or that they bind
to thehydrolytic site, block [3H]cAMPhydrolysis, but are not
hydrolyzed themselves. Although direct hydrolysis studies
were conducted using only the adipocyte phosphodiesterase,
a comparison of phosphodiesterase 150 values from both cell
types suggests that theenzymes are similar, but probably not
identical.
Consideration was given to several possible artifacts which
could be responsible for these results. The discriminative
action of insulin does not appear to be due to anelevation of
endogenous cAMP resulting from inhibition of phosphodiesterase by some analogs but not others. A recent study had
demonstrated that cAMP analogs actually decrease endogenous cAMP levels (42). It could possibly be argued that cAMP
analogs cause Ca2+mobilization and alter hepatocyte phosphorylase activity by stimulating phosphorylase kinase. It has
been shown that high concentrations of glucagon (lo-’ M),
which fully activate protein kinase and phosphorylase, raise
intracellular Ca2+,but possibly via a protein kinase mechanism (43). These conditions are in contrastto theconditions
used in the present studies where optimal insulin inhibition
is observed when phosphorylase is activated by only 20-40%
of the maximal response. Nonspecific alterations of intracellular cAMP analogs by mechanisms other than phosphodiesterase hydrolysis have been studied for only some analogs
(44). However, that such a mechanism could be responsible
for these results seems unlikely due to thediversity of cAMP
analogs within the two groups whose responses are blocked,
or not blocked, by insulin.
Recently, studies of the effects of insulin on hepatocyte
glucose production stimulated by 8-bromo-CAMP (23) and
adipocyte lipolysis stimulated by 8-thiomethyl- and 8-thioisopropyl-CAMP have been reported (24). From these experiments and others, and in contrast to the conclusions of the
present paper, the authorsconcluded that insulin does not act
through phosphodiesterase activation. The results inthe present paper, using these same three cAMP analogs in thesame

cell types, are in agreement, i.e. insulin blocks these cAMP
analog-stimulated responses. However, the interpretations of
these results are completely different. Part of this is due to
the use of a large number of cAMP analogs in both cell types
in the present paper, and indeed some analog responses are
not inhibitedby insulin. The prevailing view in theliterature
that many cAMP analogs are poorly hydrolyzed is correct.
Compared to CAMP, most analogs are relatively poor substrates for the phosphodiesterase. However, in the present
study, several cAMP analogs with low 150 values are shown to
be hydrolyzed using a sensitive, direct method.
Several studies have shown that cell responses to isobutylmethylxanthine and other phosphodiesterase inhibitors are
inhibited by insulin (2, 23, 24, and this study). It has been
argued that retention of an inhibitory effect of insulin in the
presence of phosphodiesterase inhibition suggests that insulin
does not act through phosphodiesterase (23, 24). While this
seems logical, the differential action of insulin in cAMP
analog responses suggests that thisconclusion requires reconsideration. Although isobutylmethylxanthine has a low Kifor
phosphodiesterase inhibition (16), the inhibition is likely not
complete, suggesting that only a small amount of phosphodiesterase activity is required for the insulin effect. This is
consistent with the observation that some analogs require
concentrations 20-100 times greater than cAMP for hydrolysis, yet insulin still blocks the response to these analogs. It
is possible that insulin as well as agentswhich elevate endogenous cAMP stimulate a common (16, 45) or a different (46)
phosphodiesterase. Arecent study has suggested that the
elevation of cAMP and the activation of the protein kinase
result in a feedback inhibition to “dampen” the rise in cAMP
(42). This system may act in concert with a possible insulin
stimulation of phosphodiesterase. Although this has notbeen
proved, it is consistent with results that show endogenous
cAMP must be elevated before insulin can lower the cyclic
nucleotide.
In the course of these studies, a number of observations
have been made on the cAMP analog potency in intact cells.
All analogs used in thepresent studycan fully activate protein
kinase in vitro. Cyclic nucleotide analogs can be good in vivo
protein kinase agonists if they reach effective concentrations
in the cell. The principles of analog efficacy appear to be
based on fundamental pharmacological principles of drug
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action whichhavebeenshown
to be applicable to analog
action on adipocyte lipolysis (32). Therefore, analog efficacy
depends not only on the concentration of the analog required
to activate the protein kinase (apparent K,, e.g. agonist potency), but also on the partitioning characteristics of the
analog (partition coefficient, e.g. an indication of lipid/water
solubility) and the susceptibility of the analog to hydrolysis
by phosphodiesterases (I5oand analog hydrolysis, e.g. route of
elimination). All of these characteristics have usuallynot been
dealt with in previous reports of cAMP analog effects in intact
tissues. Comparison of the efficacy of cAMP analogs in adipocytes and hepatocytes in this paper also suggests that the
porosity of the cell membrane and thelipid content of the cell
may also be important.
The hepatocyte response is 100-1000 times more sensitive
to cAMP analog stimulation than the adipocyte response.
Since there areonly minor differences in analog specificity of
the protein kinases (this study, 37) and low K , phosphodiesterase between these cell types, other factors are probably
responsible for these differences. Perhaps a different level of
phosphodiesterase activity, rather than a difference in specificity of this enzyme, could account for the differences. A
second possibility may bea relative “leakiness”of hepatocyte
membranes. Another factor could be the high lipid to cytoplasm ratio of adipocytes compared to hepatocytes. Analogs
with high partition coefficients maynot readily reach effective
concentrations in thecytoplasm because they become trapped
in the lipid of the adipocytes. Mooney et al. (47) have suggested that compartmentalization of enzymes involvedin the
lipolytic response may provide a second permeability barrier
to theanalog. Althoughthe reasons for these potency differences are not known, one or more of these factors are probably
involved. In any case, other cell types will presumably respond
differently, and it maybepossible
to use certain cAMP
analogs in the whole organism to selectively stimulate some
cell types and not others.
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